Literature DB >> 28483518

STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback.

Ruolan Zeng1, Youhong Tang2, Hui Zhou3, Yiping Liu4, Junhui Huang5, Li Li6, Wei Liu7, Yuhua Feng8, Yangying Zhou9, Taili Chen10, Lu Zhang11, Meizuo Zhong12.   

Abstract

Burkitt lymphoma (BL) is a highly aggressive B-cell neoplasm. Although BL is relatively sensitive to chemotherapy, some patients do not respond to initial therapy or relapse after standard therapy, which leads to poor prognosis. The mechanisms underlying BL chemoresistance remain poorly defined. Here, we report a mechanism for the relationship between the phosphorylation of STAT3 on Tyr705 and BL chemoresistance. In chemoresistant BL cells, STAT3 was activated and phosphorylated on Tyr705 in response to the generation of the reactive oxygen species (ROS), which induced Src Tyr416 phosphorylation after multi-chemotherapeutics treatment. As a transcription factor, the elevated phosphorylation level of STAT3Y705 increased the expression of GPx1 and SOD2, both of which protected cells against oxidative damage. Our findings revealed that the ROS-Src-STAT3-antioxidation pathway mediated negative feedback inhibition of apoptosis induced by chemotherapy. Thus, the phosphorylation of STAT3 on Tyr705 might be a target for the chemo-sensitization of BL.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Burkitt lymphoma; Buthionine-sulfoximine (PubChem CID: 21157); Cryptotanshinone (PubChem CID: 160254); Cyclophosphamide (PubChem CID: 22420); DCFH-DA (PubChem CID: 104913); Doxorubicin (PubChem CID: 31703); Glutathione peroxidase 1; Multidrug resistance; N-Acetyl-l-cysteine (PubChem CID: 12035); Reactive oxygen species; STAT3; Superoxide dismutase 2; Vincristine (PubChem CID: 5978)

Mesh:

Substances:

Year:  2017        PMID: 28483518     DOI: 10.1016/j.bbrc.2017.05.031

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumour cell killing and hydroxyl radical production in human NCI/ADR-RES cancer cells despite high-level P-glycoprotein expression.

Authors:  James H Doroshow; Agnes Juhasz
Journal:  Free Radic Res       Date:  2019-07-30

2.  ATPase inhibitory factor 1 inhibition improves the antitumor of YC-1 against hepatocellular carcinoma.

Authors:  Xuemei Ding; Jian Kong; Wenlei Xu; Shuying Dong; Yingrui Du; Changyu Yao; Jun Gao; Shan Ke; Shaohong Wang; Wenbing Sun
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

3.  Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.

Authors:  Mustafa Al-Kawaaz; Teresa Sanchez; Michael J Kluk
Journal:  J Hematop       Date:  2019-04-27       Impact factor: 0.196

4.  [Mechanism of STAT3 phosphorylation mediated leukemia cells resistance to doxorubicin].

Authors:  Z X Jia; X Z Lu; X H Cai; W Qin; W M Han; R Xiao; M Zhou; W Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

5.  Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.

Authors:  Yangying Zhou; Zhijie Xu; Wei Lin; Yumei Duan; Can Lu; Wei Liu; Weiping Su; Yuanliang Yan; Huan Liu; Li Liu; Meizuo Zhong; Jianhua Zhou; Hong Zhu
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

Review 6.  Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer.

Authors:  Teodora Costea; Oana Cezara Vlad; Luminita-Claudia Miclea; Constanta Ganea; János Szöllősi; Maria-Magdalena Mocanu
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

7.  [Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].

Authors:  D Y Tu; M Zhang; W J Yin; L Y Xu; W Sang; Z Y Li; K L Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.